These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30688000)

  • 1. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
    Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
    Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
    Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
    Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer's Disease With Amyloid-PET.
    Takahashi M; Tada T; Nakamura T; Koyama K; Momose T
    Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):314-321. PubMed ID: 30966759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline.
    Sanabria A; Alegret M; Rodriguez-Gomez O; Valero S; Sotolongo-Grau O; Monté-Rubio G; Abdelnour C; Espinosa A; Ortega G; Perez-Cordon A; Gailhajanet A; Hernandez I; Rosende-Roca M; Vargas L; Mauleon A; Sanchez D; Martin E; Rentz DM; Lomeña F; Ruiz A; Tarraga L; Boada M;
    Sci Rep; 2018 Feb; 8(1):3828. PubMed ID: 29491481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.
    Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM
    Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
    Caprioglio C; Ribaldi F; Visser LNC; Minguillon C; Collij LE; Grau-Rivera O; Zeyen P; Molinuevo JL; Gispert JD; Garibotto V; Moro C; Walker Z; Edison P; Demonet JF; Barkhof F; Scheltens P; Alves IL; Gismondi R; Farrar G; Stephens AW; Jessen F; Frisoni GB; Altomare D;
    JAMA Netw Open; 2023 Jan; 6(1):e2250921. PubMed ID: 36637820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported confusion is related to global and regional β-amyloid: data from the Women's healthy ageing project.
    McCluskey GE; Yates P; Villemagne VL; Rowe C; Szoeke CEI
    Brain Imaging Behav; 2018 Feb; 12(1):78-86. PubMed ID: 28108945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.
    Hollands S; Lim YY; Buckley R; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Lautenschlager N; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P
    J Alzheimers Dis; 2015; 43(2):677-86. PubMed ID: 25114076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories.
    Kim HJ; Yang JJ; Kwon H; Kim C; Lee JM; Chun P; Kim YJ; Jung NY; Chin J; Kim S; Woo SY; Choe YS; Lee KH; Kim ST; Kim JS; Lee JH; Weiner MW; Na DL; Seo SW
    Brain; 2016 Sep; 139(Pt 9):2516-27. PubMed ID: 27329772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly.
    Vogel JW; Varga Doležalová M; La Joie R; Marks SM; Schwimmer HD; Landau SM; Jagust WJ
    Neurology; 2017 Nov; 89(19):2002-2009. PubMed ID: 28986416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
    Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Subjective Memory Complaints with the Left Parahippocampal Amyloid Burden in Mild Cognitive Impairment.
    Choo IH; Chong A; Chung JY; Kim H
    J Alzheimers Dis; 2019; 72(4):1261-1268. PubMed ID: 31707367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer's disease preclinical phase evaluated by dual-phase
    Kim GH; Kim BR; Yoon HJ; Jeong JH
    Sci Rep; 2024 Aug; 14(1):18480. PubMed ID: 39122860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.
    Verdile G; Laws SM; Henley D; Ames D; Bush AI; Ellis KA; Faux NG; Gupta VB; Li QX; Masters CL; Pike KE; Rowe CC; Szoeke C; Taddei K; Villemagne VL; Martins RN;
    Mol Psychiatry; 2014 Jan; 19(1):69-75. PubMed ID: 23089633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.